AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pacira Biosciences Shares Rise After Upgrade and Collaboration Announcement
ByAinvest
Friday, Jul 25, 2025 2:52 pm ET1min read
Pacira Biosciences shares rise after an upgrade from Truist to "Buy" from "Hold," with a raised price target of $30 from $28. The company also announces a strategic collaboration with Johnson & Johnson Medtech to expand Zilretta promotional efforts. Additionally, Pacira BioSciences announces a workforce reduction and unveils three-year clinical data for its gene therapy, PCRX-201, in patients with osteoarthritis of the knee.
Pacira Biosciences Inc. (NASDAQ: PCRX) saw its shares rise on July 2, 2025, following an upgrade from Truist to "Buy" from "Hold," with a raised price target of $30 from $28. The positive analyst sentiment was accompanied by the company's strategic collaboration with Johnson & Johnson MedTech to expand promotional efforts for its ZILRETTA® treatment [1].The collaboration, announced on July 22, 2025, aims to significantly enhance the market reach of ZILRETTA, an extended-release treatment for osteoarthritis knee pain. Pacira's CEO, Frank D. Lee, stated that the partnership aligns with the company's 5x30 strategy, which focuses on leveraging innovative collaborations to drive growth and improve patient outcomes [1].
The agreement will see Johnson & Johnson MedTech's early intervention sales force co-promote ZILRETTA to existing and new customers, expanding access to the treatment. This move is expected to extend ZILRETTA's reach beyond orthopedic practices into additional physician specialties, such as sports medicine, pain management, and rheumatology [1].
Additionally, Pacira BioSciences announced a workforce reduction and unveiled three-year clinical data for its gene therapy, PCRX-201, in patients with osteoarthritis of the knee. The company has been advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis [1].
The stock market's positive reaction to these developments underscores investor confidence in Pacira's strategic initiatives and the potential of its innovative treatments. The company's focus on non-opioid pain therapies and strategic collaborations is likely to continue driving its growth and market presence.
References:
[1] https://www.biospace.com/press-releases/pacira-biosciences-announces-strategic-collaboration-to-significantly-expand-zilretta-promotional-efforts
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet